The Next Chapter: Using Imaging and Biomarkers to Guide AMD Management

The Next Chapter Using Imaging and Biomarkers to Guide AMD Management
Media formats available:
Details
Presenters
  • Overview

    This panel discussion will focus on fluid biomarkers and their association with long-term visual outcomes for patients with neovascular age-related macular degeneration. The faculty will debate key clinical trial data/post hoc analyses in addition to real-world experience.

    This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Describe the current treatments available to treat neovascular age-related macular degeneration (nAMD)
    • Discuss the considerations involved in the choice of anti-VEGF agent and tailoring treatment regimens for individual patients
    • Evaluate clinical evidence for biomarkers that are prognostic of optimal visual outcomes
    • Summarize the advances in VEGF inhibition that may improve treatment outcomes and/or treatment burden in nAMD
    • Accreditation

      Provided by Evolve Medical Education 

      Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
      Evolve designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • Participation Method

      In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

    • Faculty and Disclosures

      Diana V. Do, MD

      Diana V. Do, MD

      Vice Chair of Clinical Affairs
      Professor of Ophthalmology
      Byers Eye Institute
      Stanford University School of Medicine
      Palo Alto, CA


      Adrienne W. Scott, MD

      Adrienne W. Scott, MD

      Associate Professor of Ophthalmology
      Wilmer Eye Institute
      Johns Hopkins University School of Medicine
      Baltimore & Bel Air, MD


      Ankoor R. Shah, MD

      Ankoor R. Shah, MD

      Medical and Surgical Retina Specialist
      Retina Consultants of Texas
      Bellaire, TX


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

      The following faculty/staff members have the following financial relationships with ineligible companies.

      Diana V. Do, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Apellis Pharmaceuticals, Boehringer Ingelheim, Genentech, Iveric Bio, Kodiak Sciences, Kriya, and Regeneron. Grant/Research Support: Belite Bio, Boehringer Ingelheim, Kriya, and Regeneron. Shareholder: Kodiak Sciences.

      Adrienne W. Scott, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie/Allergan, Apellis Pharmaceuticals, EyePoint Pharmaceuticals, Genentech, Iveric Bio, and Regeneron. Grant/Research Support: Genentech. Speaker's Bureau: AbbVie/Allergan and DORC.

      Ankoor R. Shah, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Notal Vision, Regeneron, and Regenxbio. Shareholder: Apellis Pharmaceuticals.

      The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Regeneron Pharmaceuticals, Inc.
      This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Release Date:

      Expiration Date:

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free